Objectives: To evaluate the relationship between metabolic syndrome (MetS) and annual prostate growth rates in Chinese patients of different age decades with benign prostatic hyperplasia (BPH). Methods: We retrospectively analyzed the clinical data obtained from 1,052 Chinese men with BPH. Overnight fasting venous blood specimens were collected and serum levels of prostate-specific antigen, fasting blood glucose, high-density lipoprotein cholesterol, total cholesterol and triglyceride were recorded. We divided age into four groups: 50 ≤ age ≤ 60, 60 < age ≤ 70, 70 < age ≤ 80 and 80 < age ≤ 90. Pearson's correlation coefficient was used to test the linearity of the relationships between each of the MetS components and prostate volume and annual prostate growth rates generally and in different age decades. Results: The median total prostate volume (69.01 ml) and median annual prostate growth rate (1.92 ml/year) were significantly higher in the MetS group compared with the non-MetS group (57.26 ml and 1.23 ml/year). Significant positive correlations were also found in total prostate volume and different age decades, while negative correlations were seen in annual prostate growth rate and different age decades. Conclusions: MetS is associated with an increased risk of total volume and annual prostate growth rate in BPH patients of different age decades.

1.
Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
2.
Platz EA, Smit E, Curhan GC, Nyberg LM, Giovannucci E: Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 2002;59:877-883.
3.
Lee C, Kozlowski JM, Grayhack JT: Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995;22:237-246.
4.
Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC: Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405-409.
5.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
6.
Post JM, Beebe-Dimmer JL, Morgenstern H, Neslund-Dudas C, Bock CH, Nock N, Rundle A, Jankowski M, Rybicki BA: The metabolic syndrome and biochemical recurrence following radical prostatectomy. Prostate Cancer 2011;2011:245642.
7.
Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW: PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 2011;82:220-236.
8.
Donnell RF: Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr Opin Urol 2011;21:22-26.
9.
Vikram A, Jena GB, Ramarao P: Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010;70:79-89.
10.
Vovk EI, Vertkin AL, Zaĭrat'iants OV, Mishutchenko OP: Benign prostate hyperplasia as an age-related problem. Arkh Patol 2008;70:55-59.
11.
Ejike CE, Ezeanyika LU: Metabolic syndrome in sub-Saharan Africa: ‘smaller twin' of a region's prostatic diseases? Int Urol Nephrol 2008;40:909-920.
12.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A: The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-206.
13.
Hammarsten J, Hogstedt B: Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-158.
14.
Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D: Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-162.
15.
Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW: Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599-604.
16.
Ho CK, Habib FK: Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol 2011;8:29-41.
17.
Zeng QS, Xu CL, Liu ZY, Wang HQ, Yang B, Xu WD, Jin TL, Wu CY, Huang G, Li Z, Wang B, Sun YH: Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging men. Asian J Androl 2012;14:773-777.
18.
Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, Willett WC: Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994;140:989-1002.
19.
Landsberg L: Diet, obesity and hypertension: a hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081-1090.
20.
McVary KT: Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838-845.
21.
Peehl DM, Cohen P, Rosenfeld RG: The role of insulin-like growth factors in prostate biology. J Androl 1996;17:2-4.
22.
Kasturi S, Russell S, McVary KT: Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006;7:288-292.
23.
Shieh SM, Sheu WH, Shen DC, Fuh MM, Chen YD, Reaven GM: Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992;5:827-831.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.